Fidelity National Information Servcs Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Fidelity National Information Servcs Inc trades at $34.49 (market cap $17.71B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.32 (market cap $2.27B). The key difference: Fidelity National Information Servcs Inc is far larger — about 7.8× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| FIS | SLS | |
|---|---|---|
Market Cap | $17.71B | $2.27B |
Volume | 9,047,825 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $68.57 | $15.46 |
52-Week Low | $32.44 | $1.39 |
Typical Hold Time | 88 Days | — |
Enterprise Value | $38.22B | $2.14B |
Dividend Yield | 5.13% | — |
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal and neutral oscillators. The stock shows attractive valuation with a P/E of 5.2 and P/S of 1.44, supported by a 27.65% net income margin and 22.33% ROE. Recent earnings beat expectations in Q1 and Q2 2026, and the company secured multiple core banking client wins, enhancing growth prospects.
Outlook is positive given low valuations and earnings momentum, but risks include high debt levels and inconsistent cash flow. Analyst consensus is bullish with a $47.54 price target, implying significant upside. Investors should monitor execution on revenue growth and debt management.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →